A retrospective study evaluating effect of influenza vaccination on immune-related adverse events in patients receiving single-agent immune checkpoint inhibitors for the treatment of cancer
Latest Information Update: 16 Jul 2021
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Lung cancer; Malignant melanoma
- Focus Adverse reactions
Most Recent Events
- 16 Jul 2021 New trial record
- 08 Jun 2021 Primary endpoint ( difference in irAEs in those who received an influenza vaccine versus those who did not ) has not been met as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology